Establishment Labs Financials
ESTA Stock | USD 37.51 1.81 4.60% |
Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
---|---|---|---|---|---|---|---|---|---|
Current Ratio | 2.66 | 3.0604 |
|
|
Investors should never underestimate Establishment Labs' ability to pay suppliers on time, ensure interest payments are not accumulating, and correctly time where and how to reinvest extra cash. Individual investors need to monitor Establishment Labs' cash flow, debt, and profitability to make informed and accurate decisions about investing in Establishment Labs Holdings.
Net Income |
|
Establishment | Select Account or Indicator |
Understanding current and past Establishment Labs Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Establishment Labs' financial statements are interrelated, with each one affecting the others. For example, an increase in Establishment Labs' assets may result in an increase in income on the income statement.
Establishment Labs Earnings Geography
Please note, the presentation of Establishment Labs' financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Establishment Labs' management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Establishment Labs' management manipulating its earnings.
Establishment Labs Stock Summary
Establishment Labs competes with Streamline Health, HealthStream, National Research, Privia Health, and Evolent Health. Establishment Labs Holdings Inc., a medical technology company, manufactures and markets medical devices for aesthetic and reconstructive plastic surgery. Establishment Labs Holdings Inc. was incorporated in 2004 and is headquartered in Alajuela, Costa Rica. Establishment Labs is traded on NASDAQ Exchange in the United States.Foreign Associate | Indonesia |
Specialization | Health Care, Health Care Equipment & Services |
Instrument | USA Stock View All |
Exchange | NASDAQ Exchange |
ISIN | VGG312491084 |
CUSIP | G31249108 |
Location | British Virgin Islands |
Business Address | Building B15 and |
Sector | Health Care Equipment & Supplies |
Industry | Health Care |
Benchmark | Dow Jones Industrial |
Website | www.establishmentlabs.com |
Phone | 506 2434 2400 |
Currency | USD - US Dollar |
Establishment Labs Key Financial Ratios
Return On Equity | -2.23 | ||||
Profit Margin | (0.46) % | ||||
Operating Margin | (0.33) % | ||||
Price To Sales | 7.05 X | ||||
Revenue | 165.15 M |
Establishment Labs Key Balance Sheet Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 116.5M | 156.4M | 139.5M | 211.1M | 268.6M | 150.6M | |
Other Current Liab | 11.8M | 14.2M | 16.2M | 16.5M | 12.8M | 14.5M | |
Other Liab | 5.5M | 3.8M | 3.1M | 1.6M | 1.5M | 1.4M | |
Net Tangible Assets | 35.7M | 70.3M | 45.9M | (13.3M) | (15.2M) | (14.5M) | |
Net Debt | 10.5M | (32.8M) | 391K | 112.3M | 152.2M | 159.8M | |
Retained Earnings | (127.1M) | (165.2M) | (206.4M) | (281.6M) | (360.1M) | (342.1M) | |
Accounts Payable | 10.4M | 9.7M | 14.5M | 20.0M | 41.6M | 43.7M | |
Cash | 37.7M | 84.5M | 53.4M | 66.4M | 40.0M | 47.6M | |
Other Assets | 368K | 664K | 558K | 1.3M | 1.5M | 785.7K | |
Net Receivables | 22.8M | 19.1M | 24.4M | 35.4M | 46.9M | 25.6M | |
Capital Surpluse | 21.2M | 26.7M | 36.6M | 49.9M | 57.4M | 60.3M | |
Inventory | 28.7M | 23.2M | 28.4M | 36.6M | 79.9M | 83.9M | |
Other Current Assets | 1.3M | 5.4M | 7.0M | 11.5M | 8.0M | 5.6M | |
Total Liab | 76.9M | 81.4M | 88.8M | 219.2M | 250.2M | 262.8M | |
Total Current Assets | 95.8M | 132.3M | 113.3M | 149.9M | 174.9M | 112.4M | |
Short Term Debt | 258K | 948K | 402K | 688K | 773K | 734.4K | |
Intangible Assets | 3.4M | 4.1M | 4.4M | 4.6M | 8.0M | 4.6M | |
Common Stock | 147.7M | 213.5M | 219.7M | 223.6M | 315.6M | 180.7M | |
Long Term Debt | 48.1M | 49.8M | 51.9M | 175.5M | 188.7M | 198.2M | |
Net Invested Capital | 87.8M | 124.8M | 102.6M | 175.5M | 207.1M | 127.1M | |
Net Working Capital | 72.6M | 106.4M | 81.4M | 110.9M | 117.8M | 87.1M |
Establishment Labs Key Income Statement Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Interest Income | 4K | 15K | 23K | 87K | 541K | 568.1K | |
Interest Expense | 8.7M | 9.4M | 9.1M | 11.8M | 15.4M | 9.4M | |
Total Revenue | 89.6M | 84.7M | 126.7M | 161.7M | 165.2M | 92.0M | |
Gross Profit | 54.9M | 52.5M | 85.4M | 106.6M | 107.0M | 58.1M | |
Operating Income | (30.9M) | (27.9M) | (25.1M) | (39.7M) | (65.0M) | (61.8M) | |
Cost Of Revenue | 34.7M | 32.2M | 41.3M | 55.1M | 58.2M | 34.0M | |
Income Before Tax | (37.5M) | (38.0M) | (39.7M) | (72.8M) | (78.6M) | (74.7M) | |
Net Income | (38.2M) | (38.1M) | (41.1M) | (75.2M) | (78.5M) | (74.6M) | |
Tax Provision | 640K | 104K | 1.4M | 2.4M | 3.2M | 3.4M | |
Net Interest Income | (8.7M) | (9.4M) | (9.0M) | (11.7M) | (12.7M) | (13.3M) | |
Ebit | (30.9M) | (28.6M) | (30.7M) | (61.1M) | (63.2M) | (60.0M) | |
Research Development | 15.0M | 13.8M | 18.3M | 20.3M | 26.4M | 16.0M | |
Ebitda | (32.1M) | (24.9M) | (26.5M) | (56.9M) | (58.3M) | (55.4M) | |
Income Tax Expense | 640K | 104K | 1.4M | 2.4M | (81K) | (77.0K) |
Establishment Labs Key Cash Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Change To Inventory | (3.4M) | 4.8M | (7.6M) | (10.9M) | (42.2M) | (40.1M) | |
Investments | (7.8M) | (5.6M) | (7.2M) | (34.8M) | (24.5M) | (23.3M) | |
Change In Cash | (15.0M) | 46.9M | (31.1M) | 12.9M | (26.3M) | (25.0M) | |
Net Borrowings | 24.5M | (277K) | (175K) | 96.4M | 110.9M | 116.4M | |
Free Cash Flow | (37.0M) | (16.4M) | (34.3M) | (86.4M) | (112.4M) | (106.8M) | |
Depreciation | 3.3M | 3.7M | 4.1M | 4.3M | 4.9M | 3.5M | |
Other Non Cash Items | 2.2M | 1.4M | 5.5M | 26.8M | 8.6M | 8.2M | |
Capital Expenditures | 7.0M | 3.9M | 6.7M | 34.3M | 24.5M | 12.3M | |
Net Income | (38.2M) | (38.1M) | (41.1M) | (75.2M) | (78.5M) | (74.6M) | |
End Period Cash Flow | 37.7M | 84.5M | 53.4M | 66.4M | 40.0M | 47.6M | |
Change To Netincome | 7.1M | 2.2M | 13.8M | 22.1M | 25.4M | 26.6M |
Establishment Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Establishment Labs's current stock value. Our valuation model uses many indicators to compare Establishment Labs value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Establishment Labs competition to find correlations between indicators driving Establishment Labs's intrinsic value. More Info.Establishment Labs Holdings is rated below average in return on equity category among its peers. It is rated below average in return on asset category among its peers . At present, Establishment Labs' Return On Equity is projected to slightly decrease based on the last few years of reporting. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Establishment Labs' earnings, one of the primary drivers of an investment's value.Establishment Labs' Earnings Breakdown by Geography
Establishment Labs Systematic Risk
Establishment Labs' systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Establishment Labs volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
Incorrect Input. Please change your parameters or increase the time horizon required for running this function. The output start index for this execution was zero with a total number of output elements of zero. The Beta measures systematic risk based on how returns on Establishment Labs correlated with the market. If Beta is less than 0 Establishment Labs generally moves in the opposite direction as compared to the market. If Establishment Labs Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Establishment Labs is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Establishment Labs is generally in the same direction as the market. If Beta > 1 Establishment Labs moves generally in the same direction as, but more than the movement of the benchmark.
Establishment Labs Thematic Clasifications
Establishment Labs Holdings is part of Medical Equipment investing theme. If you are a theme-oriented, socially responsible, and at the same time, a result-driven investor, you can align your investing habits with your values without jeopardizing your expectations about returns. You can easily create an optimal portfolio of stocks, ETFs, funds, or cryptocurrencies based on a specific theme of your liking. USA Equities from Medical Equipment industry as classified by Fama & French. Fama and French investing themes focus on testing asset pricing under different economic assumptions
This theme covers USA Equities from Medical Equipment industry as classified by Fama & French. Fama and French investing themes focus on testing asset pricing under different economic assumptions. Get More Thematic Ideas
Medical Equipment | View |
Today, most investors in Establishment Labs Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Establishment Labs' growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of Establishment Labs growth as a starting point in their analysis.
Price Earnings To Growth Ratio |
|
Establishment Labs November 15, 2024 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of Establishment Labs help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Establishment Labs Holdings. We use our internally-developed statistical techniques to arrive at the intrinsic value of Establishment Labs Holdings based on widely used predictive technical indicators. In general, we focus on analyzing Establishment Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Establishment Labs's daily price indicators and compare them against related drivers.
Information Ratio | (0.05) | |||
Maximum Drawdown | 22.26 | |||
Value At Risk | (7.22) | |||
Potential Upside | 8.04 |
Complementary Tools for Establishment Stock analysis
When running Establishment Labs' price analysis, check to measure Establishment Labs' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Establishment Labs is operating at the current time. Most of Establishment Labs' value examination focuses on studying past and present price action to predict the probability of Establishment Labs' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Establishment Labs' price. Additionally, you may evaluate how the addition of Establishment Labs to your portfolios can decrease your overall portfolio volatility.
Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges |